Sustained release of a novel anti-quorum-sensing agent against oral fungal biofilms

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2265-2272

  Feldman, Mark ^a   Shenderovich, Julia ^a,b   Al Quntar, Abed Al Aziz ^a,b   Friedman, Michael ^b   Steinberg, Doron ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; EXOPOLYSACCHARIDE; THIAZOLIDINEDIONE 8; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; DELAYED RELEASE FORMULATION; POLYSACCHARIDE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL CELL; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; SUSTAINED DRUG RELEASE; THICKNESS; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; SYNTHESIS;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA ALBICANS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; POLYSACCHARIDES; QUORUM SENSING; THIAZOLIDINEDIONES;

EID: 84928919890     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04212-14     Document Type: Article

References (47)

1. Nadas GC, Taulescu MA, Ciobanu L, Fit NI, Flore C, Rapuntean S, Bouari CM, Catoi C. 2013. The interplay between NSAIDs and Candida albicans on the gastrointestinal tract of guinea pigs. Mycopathologia 175: 221-230. http://dx.doi.org/10.1007/s11046-013-9613-8.
2. Pereira CA, Toledo BC, Santos CT, Pereira Costa AC, Back-Brito GN, Kaminagakura E, Jorge AO. 2013. Opportunistic microorganisms in individuals with lesions of denture stomatitis. Diagn Microbiol Infect Dis 76:419-424. http://dx.doi.org/10.1016/j.diagmicrobio.2013.05.001.
3. Pfaller MA, Diekema DJ. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20:133-163. http://dx.doi.org/10.1128/CMR.00029-06.
4. Mayer FL, Wilson D, Hube B. 2013. Candida albicans pathogenicity mechanisms. Virulence 4:119-128. http://dx.doi.org/10.4161/viru.22913.
5. Finkel JS, Mitchell AP. 2011. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9:109-118. http://dx.doi.org/10.1038/nrmicro2475.
6. Blankenship JR, Mitchell AP. 2006. How to build a biofilm: a fungal perspective. Curr Opin Microbiol 9:588-594. http://dx.doi.org/10.1016/j.mib.2006.10.003.
7. Feldman M, Al-Quntar A, Polacheck I, Friedman M, Steinberg D. 2014. Therapeutic potential of thiazolidinedione-8 as an antibiofilm agent against Candida albicans. PLoS One 9:e93225. http://dx.doi.org/10.1371/journal.pone.0093225.
8. Srinivasan A, Uppuluri P, Lopez-Ribot J, Ramasubramanian AK. 2011. Development of a high-throughput Candida albicans biofilm chip. PLoS One 6:e19036. http://dx.doi.org/10.1371/journal.pone.0019036.
9. Kagan S, Jabbour A, Sionov E, Alquntar AA, Steinberg D, Srebnik M, Nir-Paz R, Weiss A, Polacheck I. 2014. Anti-Candida albicans biofilm effect of novel heterocyclic compounds. J Antimicrob Chemother 69:416-427. http://dx.doi.org/10.1093/jac/dkt365.
10. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 45:2475-2479. http://dx.doi.org/10.1128/AAC.45.9.2475-2479.2001.
11. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. Candida biofilms: an update. Eukaryot Cell 4:633-638. http://dx.doi.org/10.1128/EC.4.4.633-638.2005.
12. Albuquerque P, Casadevall A. 2012. Quorum sensing in fungi-a review. Med Mycol 50:337-345. http://dx.doi.org/10.3109/13693786.2011.652201.
13. Brackman G, Al Quntar AA, Enk CD, Karalic I, Nelis HJ, Van Calenbergh S, Srebnik M, Coenye T. 2013. Synthesis and evaluation of thiazolidinedione and dioxazaborocane analogues as inhibitors of AI-2 quorum sensing in Vibrio harveyi. Bioorg Med Chem 21:660-667. http://dx.doi.org/10.1016/j.bmc.2012.11.055.
14. Van Roey J, Haxaire M, Kamya M, Lwanga I, Katabira E. 2004. Comparative efficacy of topical therapy with a slow-release mucoadhesive buccal tablet containing miconazole nitrate versus systemic therapy with ketoconazole in HIV-positive patients with oropharyngeal candidiasis. J Acquir Immune Defic Syndr 35:144-150. http://dx.doi.org/10.1097/00126334-200402010-00007.
15. Rao NG, Han G, Greene JN, Tanvetyanon T, Kish JA, De Conti RC, Chuong MD, Shridhar R, Biagioli MC, Caudell JJ, Trotti AM, III. 2013. Effect of prophylactic fluconazole on oral mucositis and candidiasis during radiation therapy for head-and-neck cancer. Pract Radiat Oncol 3:229-233. http://dx.doi.org/10.1016/j.prro.2012.05.008.
16. Brito GN, Inocêncio AC, Querido SM, Jorge AO, Koga-Ito CY. 2011. In vitro antifungal susceptibility of Candida spp. oral isolates from HIVpositive patients and control individuals. Braz Oral Res 25:28-33. http://dx.doi.org/10.1590/S1806-83242011005000001.
17. George AM, Kalangi SK, Vasudevan M, Krishnaswamy NR. 2010. Chlorhexidine varnishes effectively inhibit Porphyromonas gingivalis and Streptococcus mutans-an in vivo study. J Indian Soc Periodontol 14:178-180. http://dx.doi.org/10.4103/0972-124X.75913.
18. Steinberg D, Moldovan M, Molukandov D. 2001. Testing a degradable topical varnish of cetylpyridinium chloride in an experimental dental biofilm model. J Antimicrob Chemother 48:241-243. http://dx.doi.org/10.1093/jac/48.2.241.
19. Steinberg D, Rozen R, Klausner EA, Zachs B, Friedman M. 2002. Formulation, development and characterization of sustained release varnishes containing amine and stannous fluorides. Caries Res 36:411-416. http://dx.doi.org/10.1159/000066539.
20. Steinberg D, Tal T, Friedman M. 2006. Sustained-release delivery systems of triclosan for treatment of Streptococcus mutans biofilm. J Biomed Mater Res B Appl Biomater 77B:282-286. http://dx.doi.org/10.1002/jbm.b.30266.
21. Zyskind D, Steinberg D, Friedman M, Bernimoulin JP. 1992. Inhibition of plaque accumulation under periodontal dressing by sustained-release varnish of chlorhexidine. Clin Prev Dent 14:29-33.
22. Czerninski R, Sivan S, Steinberg D, Gati I, Kagan L, Friedman M. 2010. A novel sustained-release clotrimazole varnish for local treatment of oral candidiasis. Clin Oral Investig 14:71-78. http://dx.doi.org/10.1007/s00784-009-0275-3.
23. Czerninski R, Pikovsky A, Gati I, Friedman M, Steinberg D. 28 May 2014. Comparison of the efficacy of a novel sustained release clotrimazole varnish and clotrimazole troches for the treatment of oral candidiasis. Clin Oral Investig http://dx.doi.org/10.1007/s00784-014-1259-5.
24. Gerami-Nejad M, Zacchi LF, McClellan M, Matter K, Berman J. 2013. Shuttle vectors for facile gap repair cloning and integration into a neutral locus in Candida albicans. Microbiology 159:565-579. http://dx.doi.org/10.1099/mic.0.064097-0.
25. Feldman M, Tanabe S, Howell A, Grenier D. 2012. Cranberry proanthocyanidins inhibit the adherence properties of Candida albicans and cytokine secretion by oral epithelial cells. BMC Complement Altern Med 12:6. http://dx.doi.org/10.1186/1472-6882-12-6.
26. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 183: 5385-5394. http://dx.doi.org/10.1128/JB.183.18.5385-5394.2001.
27. Gomes PN, da Silva WJ, Pousa CC, Narvaes EA, Del Bel Cury AA. 2011. Bioactivity and cellular structure of Candida albicans and Candida glabrata biofilms grown in the presence of fluconazole. Arch Oral Biol 56:1274-1281. http://dx.doi.org/10.1016/j.archoralbio.2011.04.006.
28. Privett BJ, Nutz ST, Schoenfisch MH. 2010. Efficacy of surface-generated nitric oxide against Candida albicans adhesion and biofilm formation. Biofouling 26:973-983. http://dx.doi.org/10.1080/08927014.2010.534552.
29. Ramage G, Vande Walle K, Wickes BL, Lopez-Ribot JL. 2001. Biofilm formation by Candida dubliniensis. J Clin Microbiol 39:3234-3240. http://dx.doi.org/10.1128/JCM.39.9.3234-3240.2001.
30. Powderly WG, Gallant JE, Ghannoum MA, Mayer KH, Navarro EE, Perfect JR. 1999. Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. AIDS Res Hum Retroviruses 15:1619-1623. http://dx.doi.org/10.1089/088922299309658.
31. Rex JH, Walsh TJ, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE. 2000. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 30:662-678. http://dx.doi.org/10.1086/313749.
32. Dias AP, Samaranayake LP, Lee MT. 1997. Miconazole lacquer in the treatment of denture stomatitis: clinical and microbiological findings in Chinese patients. Clin Oral Investig 1:47-52. http://dx.doi.org/10.1007/s007840050008.
33. Parvinen T, Kokko J, Yli-Urpo A. 1994. Miconazole lacquer compared with gel in treatment of denture stomatitis. Scand J Dent Res 102:361-366.
34. Friedman M, Steinberg D. 1990. Sustained-release delivery systems for treatment of dental diseases. Pharm Res 7:313-317. http://dx.doi.org/10.1023/A:1015898717936.
35. Yang W, Wiederhold NP, Williams RO, III. 2008. Drug delivery strategies for improved azole antifungal action. Expert Opin Drug Deliv 5:1199-1216. http://dx.doi.org/10.1517/17425240802457188.
36. Chavez-Dozal AA, Lown L, Jahng M, Walraven CJ, Lee SA. 2014. In vitro analysis of finasteride activity against Candida albicans urinary biofilm formation and filamentation. Antimicrob Agents Chemother 58: 5855-5862. http://dx.doi.org/10.1128/AAC.03137-14.
37. Lorenz MC, Bender JA, Fink GR. 2004. Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot Cell 3:1076-1087. http://dx.doi.org/10.1128/EC.3.5.1076-1087.2004.
38. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2:1053-1060. http://dx.doi.org/10.1128/EC.2.5.1053-1060.2003.
39. Nobile CJ, Nett JE, Andes DR, Mitchell AP. 2006. Function of Candida albicans adhesin Hwp1 in biofilm formation. Eukaryot Cell 5:1604-1610. http://dx.doi.org/10.1128/EC.00194-06.
40. Shareck J, Belhumeur P. 2011. Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell 10:1004-1012. http://dx.doi.org/10.1128/EC.05030-11.
41. Hobson RP, Munro CA, Bates S, MacCallum DM, Cutler JE, Heinsbroek SE, Brown GD, Odds FC, Gow NA. 2004. Loss of cell wall mannosylphosphate in Candida albicans does not influence macrophage recognition. J Biol Chem 279:39628-39635. http://dx.doi.org/10.1074/jbc.M405003200.
42. Baillie GS, Douglas LJ. 1998. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob Agents Chemother 42:1900-1905.
43. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin Microbiol Rev 17:255-267. http://dx.doi.org/10.1128/CMR.17.2.255-267.2004.
44. Hawser SP, Douglas LJ. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob Agents Chemother 39:2128-2131. http://dx.doi.org/10.1128/AAC.39.9.2128.
45. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, Fink GR. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949. http://dx.doi.org/10.1016/S0092-8674(00)80358-X.
46. Lal P, Sharma D, Pruthi P, Pruthi V. 2010. Exopolysaccharide analysis of biofilm-forming Candida albicans. J Appl Microbiol 109:128-136.
47. Nett JE, Sanchez H, Cain MT, Andes DR. 2010. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202:171-175. http://dx.doi.org/10.1086/651200.